Loading
Life sciences · Journal article
In Vivo · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Aim: This study aimed to investigate the impacts and underlying molecular mechanisms of E-4-(2-chloro-1-(4-methylbenzyl)-1H-indol-3-yl)but-3-en-2-one, C20H18ClNO (S4MA), a newly synthesized compound, on inflammation-associated cytokine responses in human colon cancer HCT 116 cells in vitro. Materials and Methods: Phase-contrast microscopy was utilized to detect the changes in cell morphology, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to analyze cell proliferation. Cytokine secretion was measured by enzyme-linked immunosorbent assay (ELISA), and mRNA levels were assessed by reverse transcriptase polymerase chain reaction (RT-PCR). Western blotting and confocal laser microscopy were employed to investigate the associated protein expression. Furthermore, the interaction of nuclear factor kappa-B (NF-κB) with specific DNA sequences in HCT 116 cells was evaluated using electrophoresis mobility shift assay (EMSA). Results: High concentrations of S4MA triggered cell morphological alterations in HCT 116 cells. Therefore, we reduced the concentration of S4MA to 1 μM for the inflammation-associated cytokine assay. S4MA at 0.5 and 1 μM inhibited cell proliferation. S4MA at 0.1 and 1 μM reduced the secretion of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) cytokines, and S4MA at 1 μM diminished the mRNA expression of IL-6 and TNF-α, as determined by ELISA and RT-PCR assays, respectively. Western blotting and confocal laser microscopy demonstrated that S4MA reduced the levels of signal transducer and activator of transcription 3 (STAT3)- and NF-κB-associated proteins in HCT 116 cells. Furthermore, S4MA reduced the interaction between NF-κB and its target DNA sequences within the nucleus, as determined by EMSA. Conclusion: S4MA inhibited inflammation-associated responses by regulating the STAT3/NF-κB pathways in human colon cancer HCT 116 cells. Therefore, S4MA may be a promising agent for suppressing inflammatory responses in future therapies for human colon cancer.